Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
The Big 3: CAT, NVO, VZ
12:42pm, Monday, 23'rd Dec 2024
Caterpillar (CAT) has given back all of its post-election rally, and Kenny Polcari says the stock could hover around current levels before retesting $412 in the new year. Kenny's also looking at poten
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III
11:00am, Monday, 23'rd Dec 2024
Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.
Better Buy: Eli Lilly or Novo Nordisk?
09:30am, Monday, 23'rd Dec 2024
In this video, I will cover the recent updates regarding Novo Nordisk (NVO -17.83%) and whether or not the dip is worth buying over Eli Lilly (LLY 1.35%). Watch the short video to learn more, consider
Novo Nordisk shares rebound 8%: can European markets sustain the rally?
08:28am, Monday, 23'rd Dec 2024
Novo Nordisk shares staged a dramatic rebound on Monday, recovering 8% after a steep 20% plunge on Friday. The recovery was sparked by investor reassessment of the company's potential following disapp
Eli Lilly, Novo Nordisk Stocks Rise After One Just Hit a Landmark
07:32am, Monday, 23'rd Dec 2024
Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one.
Novo Nordisk's 27% drop was market overreaction, analysts say
06:14am, Monday, 23'rd Dec 2024
Trials of semaglutide in patients with Alzheimer's and CagriSema in obese patients diabetes could give investors reason to be optimistic, Intron Health's analysts said
European Energy A/S: European Energy and Novo Holdings completes transaction regarding Joint Venture of 17 wind farms in Germany
05:10am, Monday, 23'rd Dec 2024
European Energy A/S: European Energy and Novo Holdings completes transaction regarding Joint Venture of 17 wind farms in Germany Company Announcement 21/2024 (23.12.2024) Today, European Energy A/S ha
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
06:48am, Saturday, 21'st Dec 2024
Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too?
US FDA approves Novo Nordisk's bleeding disorder drug
06:42pm, Friday, 20'th Dec 2024
The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes in patients with a type of blood-related disorder called hemophilia A, the a
BMO's Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints
05:44pm, Friday, 20'th Dec 2024
Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.
Novo Nordisk price target lowered to $105 from $155 at TD Cowen
03:41pm, Friday, 20'th Dec 2024
TD Cowen lowered the firm's price target on Novo Nordisk to $105 from $155 and keeps a Buy rating on the shares.
BMO lowers Novo Nordisk price target to $105, says reaction to data 'overdone'
02:28pm, Friday, 20'th Dec 2024
BMO Capital lowered the firm's price target on Novo Nordisk (NVO) to $105 from $156 and keeps an Outperform rating on the shares after CagriSema's Phase 3 data readout failed to meet investor expectat
Novo Nordisk: Why the stock of the Danish pharmaceutical giant is plunging
02:20pm, Friday, 20'th Dec 2024
Emily Field, Barclays head of European pharmaceutical research, joins CNBC's 'The Exchange' to discuss why Novo Nordisk shares are falling, the competition in the weight-loss drug space, and more.
Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture
02:05pm, Friday, 20'th Dec 2024
The CNBC 'Halftime Report' Investment Committee discusses today's market movers.
Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelms
01:40pm, Friday, 20'th Dec 2024
CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight-loss aid, has failed to meet expectations in late-stage trials, sending shares of the pharmaceutical giant tumblin
